Author:
Ullah Farhan,Mani Hariharasudan,Wazir Maha,Hussain Sana,Ali Saeed,Ahmad Sarfraz
Publisher
Springer International Publishing
Reference99 articles.
1. Amable, L. (2016). Cisplatin resistance and opportunities for precision medicine. Pharmacological Research, 106, 27–36.
2. Aprile, G., Macerelli, M., Maglio, G. D., Pizzolitto, S., & Fasola, G. (2013). Relevance of BRAF and extended RAS mutational analyses for metastatic colorectal cancer patients. Crit Rev OA Mol Oncol, 1(1), 7.
3. Bacher, J. W., Flanagan, L. A., Smalley, R. L., et al. (2004). Development of a fluorescent multiplex assay for detection of MSI-High tumors. Disease Markers, 20(4–5), 237–250.
4. Baker, J. B., Dutta, D., Watson, D., et al. (2011). Tumor gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer, 104(3), 488–495.
5. Barrier, A., Boelle, P.-Y., Roser, F., et al. (2006). Stage II colon cancer prognosis prediction by tumor gene expression profiling. Journal of Clinical Oncology, 24(29), 4685–4691.